2025 first_quarter Filing
Q1Lobbying Activities
Issues related to the cost of prescription drugs. Issues pertaining to coverage and reimbursement of biosimilars. Issues related to Part D coverage of generic drugs, including Part D redesign. Issues relating to the impact of prescription drug negotiation on generic drugs and biosimilars. Issues related to Medicare Part D reform. Issues related to drug shortages
- Issues relating to the labeling of generic drugs. - Issues relating to the 180 day exclusivity for generics. - Issues related to medical supply chain, including supply chain safety. - Issues related to drug pricing including drug negotiation. - Issues related to Inflation Reduction Act.